Expert disagreements, alternative perspectives, and minority opinions.
“The beta-3 adrenergic receptor that AOD-9604 targets is abundantly expressed in rodent brown and white adipose tissue, but its expression in adult human white adipose is minimal. B3-AR density in human subcutaneous fat is a fraction of what is found in mouse models. The compound was optimised for a receptor that barely exists in the target tissue of the species it was designed to treat.”
Editorial Context
This is a well-documented species difference. B3-AR agonists have a history of working in rodents but failing in humans (the CL-316,243 precedent). The low expression does not mean zero activity, but it raises fundamental questions about whether the mechanism can produce clinically meaningful lipolysis in humans.
“A plasma half-life of 3-4 minutes means AOD-9604 is enzymatically degraded before it can distribute meaningfully to peripheral adipose tissue after subcutaneous injection. The compound is essentially cleared from circulation before it arrives at the fat depot. Systemic administration of a peptide with this pharmacokinetic profile is pharmacological theatre.”
Editorial Context
The half-life concern is legitimate and partially explains the Phase IIb failure. The intra-articular cartilage data, where the compound is delivered directly to the target tissue, bypasses this problem entirely. The PK critique specifically undermines subcutaneous dosing for systemic fat loss.
“AOD-9604 failed its confirmatory human trial. In any other context, that would end the story. But because grey market peptide sales are unregulated, the compound continues to generate revenue without ever needing to demonstrate efficacy. The continued promotion of AOD-9604 for fat loss is sunk cost recoupment dressed as science.”
Editorial Context
The economics are real: AOD-9604 generates revenue through grey market and clinic sales despite having failed its pivotal trial. Whether this constitutes recoupment or reflects genuine belief in the mechanism is debatable. The compound does have a confirmed mechanism; it just could not produce clinical outcomes.
“The FDA does not remove compounds from Category 2 without reason. The removal of AOD-9604 in April 2026 is a definitive regulatory signal that the agency does not consider the risk-benefit profile acceptable for compounding. Anyone interpreting this as a bureaucratic technicality is misreading the regulatory intent.”
Editorial Context
The Category 2 removal is the strongest regulatory action short of an import ban. It does not mean the compound is dangerous, specifically, but it means the FDA found insufficient evidence of safety and efficacy to justify continued compounding access. Combined with the lack of USP/NF monograph and approved drug precedent, the regulatory pathway is structurally closed.
“When a drug fails at its primary indication, pivoting to a different application based on animal models is a classic pattern for keeping the compound alive without subjecting it to the scrutiny of human trials. The cartilage pivot moves AOD-9604 into territory where human failure is harder to prove because nobody is running the trials.”
Editorial Context
This is a harsh but structurally accurate observation. The cartilage data is from 32 rabbits with no human follow-up. However, the critique is not evidence that the cartilage mechanism is invalid. It simply highlights that preclinical promise in a new indication does not redeem failure in the original one.